1 / 47

State of the DoD Pharmacy Benefit Process & Implementation

State of the DoD Pharmacy Benefit Process & Implementation. David Bretzke, PharmD Shana Trice, PharmD. Objectives. Describe the DoD P&T process Describe and discuss recent Uniform Formulary decisions and their impact on MTFs

Download Presentation

State of the DoD Pharmacy Benefit Process & Implementation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. State of the DoD Pharmacy BenefitProcess & Implementation David Bretzke, PharmD Shana Trice, PharmD

  2. Objectives • Describe the DoD P&T process • Describe and discuss recent Uniform Formulary decisions and their impact on MTFs • Describe resources available to MTFs to support local Uniform Formulary implementation plans

  3. DoD P&T Committee Beneficiary Advisory Panel PEC Clinical Operations Pharmacy Operations Center Services MTF Commander P&T Committee Providers Pharmacies Director, TMA TMA Pharmacy Program Office TMA Contracting / DSCP TRICARE Contracts Express Scripts (TMOP, TRRX support staff) Medical Patients (beneficiaries) Pharmaceutical Industry DoD Formulary Management Players

  4. Uniform Formulary Decision Cycle • Preliminary review (T-180) • P&T Committee meets (T-90) • Defines class, BCF or ECF • Request for Pricing Info (T-75) • Price Quotes Received (T-20) • P&T Committee meets (T) • Final review, recommendations • BAP meets (T+45) • Comments to TMA • TMA Director reviews & signs minutes (T+60) • Implementation of decisions (no later than T+240) 90-Day Decision Cycle

  5. Everything Happens at Once… whimper May063 Classes

  6. Drug Class Review Process • Defined in UF Final Rule • Clinical Effectiveness • Cost Effectiveness • Takes into consideration usefulness across entire MHS • Formulary Management Tools • 3rd tier (NF at MTF, $22 at Mail & Retail) • Prior Authorization • Quantity Limits • BCF / ECF

  7. Clinical Effectiveness • How a drug compares within its class • Extensive review of evidence • Overall clinical utility or usefulness • Safety, tolerability, efficacy/effectiveness • Provider opinion • Clinical coverage • Therapeutic interchangeability • How many do you need?

  8. Cost Effectiveness • Cost across MTFs, Mail Order & Retail Network • Pharmacoeconomic analysis • Primarily cost effectiveness analyses • Weigh cost and clinical attributes of individual medications • Sensitivity analyses to account for variability • Budget impact analysis • Market share migration • Cost of Medical Necessity determinations • Copay differences • Switch costs • How much are you willing to pay?

  9. Uniform Formulary Recommendations  Cost • Balance clinical and cost effectiveness = formulary status • Non-formulary drugs less clinically and/or less cost-effective • Value judgment • MTFs part of overall system More Costly, More Effective More Costly, Less Effective Maybe No NW NE Effectiveness SW SE Less Costly, Less Effective Less Costly, More Effective Maybe Yes The Cost Effectiveness Plane

  10. Implementing the Uniform Formulary • One class at a time • Not ‘on’ UF until class reviewed • New FDA-approved drugs • May prompt UF review • If class already reviewed, compared to least clinically or cost effective UF drug • BCF/ECF • BCF or ECF designation applies to class, NOT individual drug • BCF / ECF agents selected from UF agents after UF review

  11. How are Drug Classes Scheduled for UF Review? • Economic impact ($$$) • Existing contracts • Competitive nature of class • Significant clinical developments • New drugs • New clinical evidence • 80 / 20 rule • When to re-review?

  12. UF Decisions, Feb & May 05

  13. UF Decisions, Aug 05

  14. UF Recommendations, Nov 05

  15. Implementation Or, the devil is in the details…

  16. 3rd Tier PrescriptionsAll DoD =MTF + Mail Order + Retail

  17. 3rd Tier PrescriptionsMTF Only

  18. 60,000 NEXIUM - AstraZeneca 50,000 40,000 PREVACID - TAP 30,000 Retail Prescriptions PROTONIX - Wyeth OMEPRAZOLE - Generic 20,000 ACIPHEX – Eisai / J&J 10,000 0 Jul-05 Oct-05 Apr-05 Jan-05 Sep-05 Feb-05 Mar-05 Jun-05 Aug-05 Nov-04 Dec-04 May-05 Decision Date: 18 April 05 Full Implementation Date: 17 July 05 PPIsRetail Prescriptions Implementation Period Decision Date Full Implementation Date

  19. 80,000 70,000 60,000 RABEPRAZOLE 50,000 40,000 LANSOPRAZOLE 30,000 OMEPRAZOLE 20,000 10,000 ESOMEPRAZOLE PANTOPRAZOLE 0 Jul-05 Apr-05 Oct-05 Nov-05 Dec-05 Jun-05 Aug-05 May-05 Sep-05 Decision Date: 18 April 05 Full Implementation Date: 17 July 05 PPIsMTF Rxs

  20. 18,000 IRBESARTAN 16,000 VALSARTAN 14,000 12,000 LOSARTAN 10,000 8,000 6,000 TELMISARTAN CANDESARTAN 4,000 2,000 EPROSARTAN OLMESARTAN 0 Jul-05 Apr-05 Oct-05 Dec-05 Jun-05 Nov-05 Sep-05 Aug-05 May-05 Decision Date: 18 April 05 Full Implementation Date: 17 July 05 ARBsMTF Prescriptions

  21. $2.00 $1.75 Retail $1.50 Overall $1.25 $1.00 Avg Cost Per Day MTF Mail Order $0.75 $0.50 $0.25 Jul-05 Oct-05 Jan-05 Nov-04 Dec-04 Feb-05 Jun-05 Apr-05 Sep-05 Mar-05 May-05 Aug-05 Decision Date: 18 April 05 Full Implementation Date: 17 July 05 ARBsCost Per Day of Therapy – All DoD

  22. 40,000 35,000 30,000 SILDENAFIL 25,000 20,000 15,000 VARDENAFIL TADALAFIL 10,000 5,000 0 Jul-05 Apr-05 Oct-05 Jun-05 Nov-05 Dec-05 Sep-05 Aug-05 May-05 Decision Date: 14 Jul 05 Full Implementation Date: 12 Oct 05 PDE-5sAll DoD Prescriptions

  23. 18,000 16,000 14,000 SILDENAFIL 12,000 VARDENAFIL 10,000 8,000 6,000 4,000 2,000 TADALAFIL 0 Jul-05 Apr-05 Oct-05 Jun-05 Nov-05 Dec-05 Sep-05 Aug-05 May-05 Decision Date: 14 Jul 05 Full Implementation Date: 12 Oct 05 PDE-5sMTF Prescriptions

  24. Decision Date: 14 July 05 Full Implementation Date: 12 October 05 PDE-5sCost Per Tablet – All Points of Service $9.00 $8.00 Retail Overall $7.00 $6.00 Mail Order MTF $5.00 $4.00 $3.00 Jul-05 Oct-05 Nov-05 Jan-05 Jun-05 Nov-04 Feb-05 Apr-05 Dec-04 Mar-05 May-05 Sep-05 Aug-05

  25. PACER • Pharmacy Administration Cost Evaluation Reports • Reports drug use and costs • Compared to other MTFs • Pilot project • 27 selected MTFs • 5 drug classes • PPIs, ARBs, PDE-5s, CCBs, ACEs

  26. MTF Resources For UF Implementation - People • Chain of Command • MTF Commanders • Service consultants • DSCP • Local pricing or prime vendor issues • TMA Pharmacy Program Office • Policy, TRICARE contract issues • PEC • Clinical • MTF support documents • Direct dialog (phone / email) • POC • How do I know if MN or PA or QL exception already approved?

  27. MTF Resources For UF Implementation - Websites • TRICARE Pharmacy website - www.tricare.osd.mil/pharmacy • PA and MN criteria and forms • QLs • DoD P&T Committee minutes • BAP • Formulary Search Tool • PEC website – www.pec.ha.osd.mil • DoD P&T Committee review schedule • PACER reports • RxNet – www.dodrxnet.org • Documents for MTF use - class reviews, monographs, MN forms prior to effective date (Word format) • MTF Info page – summary – www.pec.ha.osd/mil/MTF/UF_Info.htm

  28. MTF Resources For UF Implementation - Websites • TRICARE Pharmacy website - www.tricare.osd.mil/pharmacy • PA and MN criteria and forms • QLs • DoD P&T Committee minutes • BAP • Formulary Search Tool • PEC website – www.pec.ha.osd.mil • DoD P&T Committee review schedule • PACER reports • RxNet – www.dodrxnet.org • Documents for MTF use - class reviews, monographs, MN forms prior to effective date (Word format) • MTF Info page – summary – www.pec.ha.osd/mil/MTF/UF_Info.htm

  29. Summary • Uniform Formulary is here • Changes are coming quickly • MTF support of UF decisions is the law, but is also vital to success • PEC is committed to provide MTF implementation support through multiple venues – but we can’t do it alone.

More Related